LinkedIn Profile

Access Cartiva historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal GICS Sector GICS Industry
private:cartiva 3508650 May 23rd, 2019 12:00AM Cartiva, Inc. 1.4K 45.00 Open Medical Devices May 23rd, 2019 11:39AM May 23rd, 2019 11:39AM Cartiva, Inc. is an evidence-based medical device company with the first and only FDA approved synthetic cartilage implant for the treatment of osteoarthritis. Cartiva’s synthetic cartilage is made of a biomedical polymer that mimics natural cartilage. The durable material is proven to withstand the repetitive compressive loads that occur clinically in the great toe joint, while the low coefficient of friction aids in smooth joint articulation and mobility. Cartiva’s implant offers patients a joint preserving alternative to fusion of the great toe with substantial pain reduction and improved range of motion and is backed by the largest and most rigorous clinical study for this condition. Cartiva is currently investigating use of its platform technology for additional indications, including near-term use in lesser metatarsal and CMC arthritis, and longer-term applications for the ankle, elbow and shoulder. Cartiva’s management team, board of directors and medical advisers are comprised of industry-recognized professionals who possess broad knowledge in orthopedics and extensive experience managing innovative medical devices from development through clinical trials, FDA approval and successful commercialization. Cartiva’s venture investors include New Enterprise Associates, Windham Venture Partners and Domain Associates. Open Open Windward Pkwy Alpharetta GA US 30005 Health Care Equipment & Services
private:cartiva 3508650 Feb 17th, 2018 12:00AM Cartiva, Inc. 966 34.00 Open Medical Devices Feb 17th, 2018 02:25PM Feb 17th, 2018 02:25PM Cartiva, Inc. is an evidence-based medical device company with the first and only FDA approved synthetic cartilage implant for the treatment of osteoarthritis. Cartiva’s synthetic cartilage is made of a biomedical polymer that mimics natural cartilage. The durable material is proven to withstand the repetitive compressive loads that occur clinically in the great toe joint, while the low coefficient of friction aids in smooth joint articulation and mobility. Cartiva’s implant offers patients a joint preserving alternative to fusion of the great toe with substantial pain reduction and improved range of motion and is backed by the largest and most rigorous clinical study for this condition. Cartiva is currently investigating use of its platform technology for additional indications, including near-term use in lesser metatarsal and CMC arthritis, and longer-term applications for the ankle, elbow and shoulder. Cartiva’s management team, board of directors and medical advisers are comprised of industry-recognized professionals who possess broad knowledge in orthopedics and extensive experience managing innovative medical devices from development through clinical trials, FDA approval and successful commercialization. Cartiva’s venture investors include New Enterprise Associates, Windham Venture Partners and Domain Associates. Health Care Equipment & Services
private:cartiva 3508650 Feb 16th, 2018 12:00AM Cartiva, Inc. 966 34.00 Open Medical Devices Feb 16th, 2017 08:15AM Feb 16th, 2017 08:15AM Cartiva, Inc. is an evidence-based medical device company with the first and only FDA approved synthetic cartilage implant for the treatment of osteoarthritis. Cartiva’s synthetic cartilage is made of a biomedical polymer that mimics natural cartilage. The durable material is proven to withstand the repetitive compressive loads that occur clinically in the great toe joint, while the low coefficient of friction aids in smooth joint articulation and mobility. Cartiva’s implant offers patients a joint preserving alternative to fusion of the great toe with substantial pain reduction and improved range of motion and is backed by the largest and most rigorous clinical study for this condition. Cartiva is currently investigating use of its platform technology for additional indications, including near-term use in lesser metatarsal and CMC arthritis, and longer-term applications for the ankle, elbow and shoulder. Cartiva’s management team, board of directors and medical advisers are comprised of industry-recognized professionals who possess broad knowledge in orthopedics and extensive experience managing innovative medical devices from development through clinical trials, FDA approval and successful commercialization. Cartiva’s venture investors include New Enterprise Associates, Windham Venture Partners and Domain Associates. Health Care Equipment & Services
private:cartiva 3508650 Feb 15th, 2018 12:00AM Cartiva, Inc. 966 34.00 Open Medical Devices Feb 15th, 2017 10:07AM Feb 15th, 2017 10:07AM Cartiva, Inc. is an evidence-based medical device company with the first and only FDA approved synthetic cartilage implant for the treatment of osteoarthritis. Cartiva’s synthetic cartilage is made of a biomedical polymer that mimics natural cartilage. The durable material is proven to withstand the repetitive compressive loads that occur clinically in the great toe joint, while the low coefficient of friction aids in smooth joint articulation and mobility. Cartiva’s implant offers patients a joint preserving alternative to fusion of the great toe with substantial pain reduction and improved range of motion and is backed by the largest and most rigorous clinical study for this condition. Cartiva is currently investigating use of its platform technology for additional indications, including near-term use in lesser metatarsal and CMC arthritis, and longer-term applications for the ankle, elbow and shoulder. Cartiva’s management team, board of directors and medical advisers are comprised of industry-recognized professionals who possess broad knowledge in orthopedics and extensive experience managing innovative medical devices from development through clinical trials, FDA approval and successful commercialization. Cartiva’s venture investors include New Enterprise Associates, Windham Venture Partners and Domain Associates. Health Care Equipment & Services
private:cartiva 3508650 Feb 14th, 2018 12:00AM Cartiva, Inc. 966 34.00 Open Medical Devices Feb 14th, 2017 01:50PM Feb 14th, 2017 01:50PM Cartiva, Inc. is an evidence-based medical device company with the first and only FDA approved synthetic cartilage implant for the treatment of osteoarthritis. Cartiva’s synthetic cartilage is made of a biomedical polymer that mimics natural cartilage. The durable material is proven to withstand the repetitive compressive loads that occur clinically in the great toe joint, while the low coefficient of friction aids in smooth joint articulation and mobility. Cartiva’s implant offers patients a joint preserving alternative to fusion of the great toe with substantial pain reduction and improved range of motion and is backed by the largest and most rigorous clinical study for this condition. Cartiva is currently investigating use of its platform technology for additional indications, including near-term use in lesser metatarsal and CMC arthritis, and longer-term applications for the ankle, elbow and shoulder. Cartiva’s management team, board of directors and medical advisers are comprised of industry-recognized professionals who possess broad knowledge in orthopedics and extensive experience managing innovative medical devices from development through clinical trials, FDA approval and successful commercialization. Cartiva’s venture investors include New Enterprise Associates, Windham Venture Partners and Domain Associates. Health Care Equipment & Services
private:cartiva 3508650 Feb 13th, 2018 12:00AM Cartiva, Inc. 966 34.00 Open Medical Devices Feb 13th, 2017 04:11PM Feb 13th, 2017 04:11PM Cartiva, Inc. is an evidence-based medical device company with the first and only FDA approved synthetic cartilage implant for the treatment of osteoarthritis. Cartiva’s synthetic cartilage is made of a biomedical polymer that mimics natural cartilage. The durable material is proven to withstand the repetitive compressive loads that occur clinically in the great toe joint, while the low coefficient of friction aids in smooth joint articulation and mobility. Cartiva’s implant offers patients a joint preserving alternative to fusion of the great toe with substantial pain reduction and improved range of motion and is backed by the largest and most rigorous clinical study for this condition. Cartiva is currently investigating use of its platform technology for additional indications, including near-term use in lesser metatarsal and CMC arthritis, and longer-term applications for the ankle, elbow and shoulder. Cartiva’s management team, board of directors and medical advisers are comprised of industry-recognized professionals who possess broad knowledge in orthopedics and extensive experience managing innovative medical devices from development through clinical trials, FDA approval and successful commercialization. Cartiva’s venture investors include New Enterprise Associates, Windham Venture Partners and Domain Associates. Health Care Equipment & Services
private:cartiva 3508650 Feb 12th, 2018 12:00AM Cartiva, Inc. 966 34.00 Open Medical Devices Feb 12th, 2017 04:15AM Feb 12th, 2017 04:15AM Cartiva, Inc. is an evidence-based medical device company with the first and only FDA approved synthetic cartilage implant for the treatment of osteoarthritis. Cartiva’s synthetic cartilage is made of a biomedical polymer that mimics natural cartilage. The durable material is proven to withstand the repetitive compressive loads that occur clinically in the great toe joint, while the low coefficient of friction aids in smooth joint articulation and mobility. Cartiva’s implant offers patients a joint preserving alternative to fusion of the great toe with substantial pain reduction and improved range of motion and is backed by the largest and most rigorous clinical study for this condition. Cartiva is currently investigating use of its platform technology for additional indications, including near-term use in lesser metatarsal and CMC arthritis, and longer-term applications for the ankle, elbow and shoulder. Cartiva’s management team, board of directors and medical advisers are comprised of industry-recognized professionals who possess broad knowledge in orthopedics and extensive experience managing innovative medical devices from development through clinical trials, FDA approval and successful commercialization. Cartiva’s venture investors include New Enterprise Associates, Windham Venture Partners and Domain Associates. Health Care Equipment & Services
private:cartiva 3508650 Feb 11th, 2018 12:00AM Cartiva, Inc. 966 34.00 Open Medical Devices Feb 11th, 2017 05:35AM Feb 11th, 2017 05:35AM Cartiva, Inc. is an evidence-based medical device company with the first and only FDA approved synthetic cartilage implant for the treatment of osteoarthritis. Cartiva’s synthetic cartilage is made of a biomedical polymer that mimics natural cartilage. The durable material is proven to withstand the repetitive compressive loads that occur clinically in the great toe joint, while the low coefficient of friction aids in smooth joint articulation and mobility. Cartiva’s implant offers patients a joint preserving alternative to fusion of the great toe with substantial pain reduction and improved range of motion and is backed by the largest and most rigorous clinical study for this condition. Cartiva is currently investigating use of its platform technology for additional indications, including near-term use in lesser metatarsal and CMC arthritis, and longer-term applications for the ankle, elbow and shoulder. Cartiva’s management team, board of directors and medical advisers are comprised of industry-recognized professionals who possess broad knowledge in orthopedics and extensive experience managing innovative medical devices from development through clinical trials, FDA approval and successful commercialization. Cartiva’s venture investors include New Enterprise Associates, Windham Venture Partners and Domain Associates. Health Care Equipment & Services
private:cartiva 3508650 Feb 10th, 2018 12:00AM Cartiva, Inc. 966 34.00 Open Medical Devices Feb 10th, 2017 06:43AM Feb 10th, 2017 06:43AM Cartiva, Inc. is an evidence-based medical device company with the first and only FDA approved synthetic cartilage implant for the treatment of osteoarthritis. Cartiva’s synthetic cartilage is made of a biomedical polymer that mimics natural cartilage. The durable material is proven to withstand the repetitive compressive loads that occur clinically in the great toe joint, while the low coefficient of friction aids in smooth joint articulation and mobility. Cartiva’s implant offers patients a joint preserving alternative to fusion of the great toe with substantial pain reduction and improved range of motion and is backed by the largest and most rigorous clinical study for this condition. Cartiva is currently investigating use of its platform technology for additional indications, including near-term use in lesser metatarsal and CMC arthritis, and longer-term applications for the ankle, elbow and shoulder. Cartiva’s management team, board of directors and medical advisers are comprised of industry-recognized professionals who possess broad knowledge in orthopedics and extensive experience managing innovative medical devices from development through clinical trials, FDA approval and successful commercialization. Cartiva’s venture investors include New Enterprise Associates, Windham Venture Partners and Domain Associates. Health Care Equipment & Services
private:cartiva 3508650 Feb 9th, 2018 12:00AM Cartiva, Inc. 966 34.00 Open Medical Devices Feb 9th, 2017 08:57AM Feb 9th, 2017 08:57AM Cartiva, Inc. is an evidence-based medical device company with the first and only FDA approved synthetic cartilage implant for the treatment of osteoarthritis. Cartiva’s synthetic cartilage is made of a biomedical polymer that mimics natural cartilage. The durable material is proven to withstand the repetitive compressive loads that occur clinically in the great toe joint, while the low coefficient of friction aids in smooth joint articulation and mobility. Cartiva’s implant offers patients a joint preserving alternative to fusion of the great toe with substantial pain reduction and improved range of motion and is backed by the largest and most rigorous clinical study for this condition. Cartiva is currently investigating use of its platform technology for additional indications, including near-term use in lesser metatarsal and CMC arthritis, and longer-term applications for the ankle, elbow and shoulder. Cartiva’s management team, board of directors and medical advisers are comprised of industry-recognized professionals who possess broad knowledge in orthopedics and extensive experience managing innovative medical devices from development through clinical trials, FDA approval and successful commercialization. Cartiva’s venture investors include New Enterprise Associates, Windham Venture Partners and Domain Associates. Health Care Equipment & Services

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.